ArticleTheranostics2023
KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8
Open access · goldFull text read
In one paragraph
Article in Theranostics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Cyclooxygenase-2 selective inhibitors in cancer prevention and therapy: inflammopharmacological basis and translational prospects.Medical oncology (Northwood, London, England) · 2026Review
- KLF5-driven TAZ-FASN signaling reprograms fatty acid metabolism to support Treg differentiation in lung cancer.Journal of translational medicine · 2026Article
- PRKN mediates the ubiquitination of SCAF8 to reduce the mRNA stability of KLF5 and its transcriptional activation of EFNA3 in colorectal cancer.Cellular & molecular biology letters · 2026Article
- COVID-19 is associated with epigenetic dysregulation in regulatory B cells linked to recurrent pregnancy loss.Cell communication and signaling : CCS · 2026Article
- KLF family of proteins in gastrointestinal tumors (Review).Oncology letters · 2026Review
- ZDHHC9-mediated KLF5 palmitoylation enhances the cAMP/PKA/CREB axis to promote colorectal cancer progression.Oncogene · 2026Article
- Semaphorin 6D drives anti-tumor type I interferon responses to reprogram the tumor microenvironment in colorectal cancer.Cell death & disease · 2026Article
- Dual-dimensional profiling of host genomic variations and HPV integration in PD-L1-stratified cervical cancer via Oxford Nanopore Technology.Journal of translational medicine · 2026Article
- Molecular Subtypes of Mixed Gastric Cancer Defined by Machine Learning for Predicting Prognosis and Treatment Response.Current medicinal chemistry · 2026Article
- Spatial omics technology potentially promotes the progress of tumor immunotherapy.British journal of cancer · 2025Review
- Hepatocellular carcinoma escapes immune surveillance through deceiving thymus into recalling peripheral activated CD8Neoplasia (New York, N.Y.) · 2025Article
- Spatial Transcriptomics Decodes Breast Cancer Microenvironment Heterogeneity: From Multidimensional Dynamic Profiling to Precision Therapy Blueprint Construction.Biomolecules · 2025Review
- A pH-sensitive peptide amphiphilic-based drug delivery system inhibits hepatocellular carcinoma growth by suppressing hepatic stellate cell activation.Materials today. Bio · 2025Article
- Exploring Immune-Related Ferroptosis Genes in Thyroid Cancer: A Comprehensive Analysis.Biomedicines · 2025Article
- Positive Feedback Regulation between KLF5 and XPO1 Promotes Cell Cycle Progression of Basal like Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer.Cancer research · 2025Article
- M2-polarized tumor-associated macrophage-secreted exosomal lncRNA NEAT1 upregulates galectin-3 by recruiting KLF5 and promotes HCC immune escape.Journal of cell communication and signaling · 2025Article
- Malignant epithelial cell marker-driven risk signature enables precise stratification in esophageal cancer.Frontiers in immunology · 2025Article
- KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.Oncogene · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 2 countries.
Qi WuKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
Zhou LiuDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Zhijie GaoDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Yao LuoMedical Faculty of Kunming University of Science and Technology, Kunming, China.
Fubing LiAcademy of Biomedical Engineering, Kunming Medical University, Kunming 650500, China.
ChuanYu YangKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
Tiantian WangSchool of Life Science, University of Science & Technology of China, Hefei, 230027, Anhui, China.
Xiangyu MengCenter for Single-Cell Omics and Tumor Liquid Biopsy, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Haijun ChenCollege of Chemistry, Fuzhou University, Fuzhou, Fujian 350108, China.
Juanjuan LiDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Yanjie KongPathology department, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen 518035, China.
Chao DongDepartment of Medical Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Si SunDepartment of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Ceshi ChenKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
Wuhan University · CNChinese Academy of Sciences · CNKunming Medical University · CNFuzhou University · CNKunming University of Science and Technology · CNRenmin Hospital of Wuhan University · CNShenzhen Second People's Hospital · CNUniversity of Hong Kong · HKUniversity of Science and Technology of China · CNZhongnan Hospital of Wuhan University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
DinoprostoneTranscription FactorsAnimalsCD8-Positive T-LymphocytesCell Line, TumorCyclooxygenase 2ImmunotherapyKruppel-Like Transcription FactorsMiceTumor MicroenvironmentCyclooxygenase 2DinoprostoneKlf5 protein, mouseKruppel-Like Transcription FactorsTranscription Factorsbreast cancerCD8+ T cellCOX2KLF5PD1 blocker
Identifiers
What OpenQuestion holds
Textfull text, public
LicenceCC BY
measurements read43
identifiers read1
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.